Paden brings to this position over 20 years of diverse experience in clinical research, including operational and scientific leadership roles, clinical trial management and monitoring, publication planning, product lifecycle management, and clinical training and education.
At Prometrika, Paden will lead clinical operations in day-to-day trial management activities and in the development of systems and procedures to further enhance the company's delivery of clinical research.
Paden's leadership roles have included head of clinical development operations at ContraFect Corp., senior consultant at Halloran Consulting, and director of clinical development medical affairs at Boehringer Ingelheim Pharmaceuticals.
Her work has covered orphan indications in oncology, cardiovascular disease, and genetic disorders.
Founded in 2003 and based in Cambridge, Massachusetts, Prometrika utilises a collaborative approach to clinical development and execution with a close-knit, highly-experienced senior leadership team involved in all phases of trials.
Prometrika's services include complete clinical operations and clinical trial management, data management, pharmacovigilance, biostatistics and programming, medical writing, and regulatory submissions.
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval